688331:SSERemeGen Co. Ltd. Class A Analysis

RemeGen is trading at CNY 112.08, comfortably above its 20‑day (≈103.66) and 50‑day (≈99.17) SMAs and well under the 52‑week high of 119, indicating a bullish price momentum supported by a bullish MACD histogram (+1.45) and a neutral‑high RSI (59.5). Volume is increasing, and the beta of 0.52 suggests modest market sensitivity despite a striking 30‑day volatility of 62.9%. Fundamentally, the company boasts an exceptional operating margin of 78.6% and profit margin of 21.8%, with a gross margin reported at 100%, reflecting strong pricing power in its biotech portfolio. However, the forward P/E of 68.7 is far above the industry average of 26.4, and the price‑to‑book of 26.7 further signals that the stock is overvalued relative to peers. The balance sheet shows a high debt‑to‑equity ratio (~94) and total debt exceeding cash, adding financial leverage concerns. Regulatory and geographic risks are elevated given the reliance on Chinese and U.S. approvals for its ADC and autoimmune pipelines, while the lack of dividend underscores a growth‑focused capital allocation. Overall, the stock presents a compelling growth narrative but at a premium price, demanding careful risk management.